FDA Approves Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved zidesamtinib, a next-generation ROS1 tyrosine kinase inhibitor, for lung cancer patients whose disease progressed after prior ROS1-targeted therapy. Data from the ARROS-1 clinical trial showed that durable responses can be achieved even in patients who developed resistance to previous treatments.

July 22, 2026 — An important development has taken place in a rare but targetable subgroup of lung cancer. As of July 22, 2026, the FDA approved Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received at least one ROS1 tyrosine kinase inhibitor (TKI).

ROS1 gene fusion is a molecular alteration found in roughly 1% to 2% of non-small cell lung cancers and is responsive to targeted therapy. Although current ROS1 inhibitors initially produce strong responses, the development of resistance and subsequent disease progression have remained a significant problem in this patient group. This approval addresses exactly that setting, opening a new line of therapy for patients whose options narrow after prior targeted treatment.

---

Durable Responses After Resistance: The ARROS-1 Study

The efficacy of the drug was evaluated in the multicenter, single-arm, open-label ARROS-1 clinical trial. The study enrolled a total of 117 patients who had previously received ROS1-targeted therapies such as lorlatinib, repotrectinib, or taletrectinib. Results confirmed by independent central review were as follows:

• Overall response rate (ORR): 44% across the full study population.
• Duration of response (DOR): Among responders, the response lasted at least 6 months in 82% of patients and at least 12 months in 69%.
• Patients previously treated with one ROS1 TKI: Overall response rate of 49%.
• Patients previously treated with two or more ROS1 TKIs: Overall response rate of 38%.

Subgroup analyses show that a meaningful response rate is maintained even in patients who had received more than one prior targeted therapy and are therefore considered more difficult to treat.

💬 Clinical Significance

In ROS1-positive lung cancer, once resistance develops after first-line targeted therapy, the remaining options largely narrow to chemotherapy. The 44% overall response rate achieved by zidesamtinib in this resistant population, together with the durability of responses beyond 12 months in a substantial share of patients, demonstrates that a new targeted step has been added to the treatment sequence. The preservation of a 38% response rate after two or more prior ROS1 inhibitors in particular suggests that the mechanisms driving resistance can be overcome with this molecule.

---

Safety and Notable Side Effects

The warnings and precautions in the drug's safety profile that require close monitoring include:

• Central nervous system reactions: Monitoring for dizziness and cognitive or behavioral changes is required.
• QTc interval prolongation: ECG and electrolyte monitoring is recommended, as cardiac rhythm may be affected.
• Interstitial lung disease / pneumonitis: New or worsening respiratory symptoms must be evaluated promptly.
• Bone fractures: Monitoring bone health during treatment is important.
• Myalgia with creatine phosphokinase (CPK) elevation: Muscle pain may occur together with elevated CPK levels.
• Pancreatic toxicity: Monitoring for elevations in pancreatic enzymes is required.
• Embryo-fetal toxicity: There is a risk of harm to the fetus during pregnancy.

Conclusion

With the approval of zidesamtinib, a new option capable of delivering durable responses has entered clinical practice for patients with ROS1-positive non-small cell lung cancer who developed resistance to prior targeted therapies. This development once again underlines how decisive the accurate identification of molecular subgroups, and the reassessment of the genetic profile throughout treatment, has become in lung cancer.